Clinical Trial Finder
Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy
Study Purpose
The rise of oral therapies in the management of cancers has considerably changed the patient care path. If the oral route is preferred by patients because it offers a better quality of life, it is not without impact for patients and the health professionals involved in their management in their care. Indeed, the use of the oral route shifts part of the responsibility for monitoring treatment towards the patient, thereby leading to compliance problems, drug interactions and the management of adverse effects.These risks can cause complications or compromise the effectiveness of treatment, and generate additional costs for the investigator's health system. The study proposes to involve Healthcare Facilities Pharmacist and the Dispensary Pharmacist with all other health professionals.First, the hospital pharmacist will operate before the initiation of an oral route to perform a clinical pharmaceutical analysis of drug prescriptions. Then after the primary prescription and finally during a follow-up consultation 3 months after the initiation of treatment. The hypothesis of the study is that the coordinated intervention of the hospital pharmacist and of the dispensary pharmacist would improve the tolerance of oral treatments by reducing the number of serious adverse effects found, as well as improve the, quality of life, patient and professional satisfaction
Recruitment Criteria
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Inclusion Criteria:
Exclusion Criteria:
- - Patient unable to undergo the medical monitoring of the trial for geographical, social
or psychological reasons.
- Patients 70 years old with cognitive disorders identified by the G-CODETrial Details
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
Arms
Experimental: Coordinated pharmaceutical path
Patients treated with anti-cancer oral therapy who benefit a specific pharmaceutical follow-up by the healthcare facilities pharmacist and by the dispensary pharmacist
No Intervention: Standard of care
Patients treated with anti-cancer oral therapy who who do not benefit from an additional pharmaceutical intervention
Interventions
Behavioral: - IPPACTTO
The coordinated experimental pharmaceutical path consists of 7 pharmaceutical interviews or consultations. One initial pharmaceutical consultation with the hospital pharmacist. Five follow-up pharmaceutical interviews with the dispensary pharmacist. One follow-up pharmaceutical consultation with hospital pharmacist. Each pharmaceutical interview or consultation will result in the drafting of a pharmaceutical report to be sent to the other participating health professionals. At each pharmaceutical consultation or interview, the pharmacists requested perform a clinical pharmaceutical analysis of drug prescriptions; Evaluate the patient's understanding; Detect adherence problems, Identify drug related problems; Alert the oncologist and / or the attending physician.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
International Sites
Status
Recruiting
Address
Institut de Cancérologie de l'Ouest
Angers, , 49055
Site Contact
Elouen BOUGHALEM, MD
[email protected]
02 40 84 64 47
Status
Recruiting
Address
CHU
Angers, , 49933
Site Contact
Mathilde HUNAULT Mathilde, MD
[email protected]
02 40 84 64 47
Status
Recruiting
Address
Ch Cholet
Cholet, , 49300
Site Contact
Victor SIMMET, MD
[email protected]
02 40 84 64 47
Status
Recruiting
Address
CHD Vendée
La Roche-sur-Yon, , 85925
Site Contact
Nadine MORINEAU Nadine, MD
[email protected]
02 40 84 64 47
Status
Recruiting
Address
Ch Le Mans
Le Mans, , 72037
Site Contact
Oana COJOCARASU, MD
[email protected]
02 40 84 64 47
Status
Recruiting
Address
Chu Nantes
Nantes, , 44093
Site Contact
Nicolas BLIN, MD
[email protected]
02 40 84 64 47
Status
Recruiting
Address
Institut de Cancérologie de l'Ouest
Saint Herblain, , 44805
Site Contact
Emmanuelle BOURBOULOUX, MD
[email protected]
02 40 84 64 47
Privacy Overview